Sally Shorthose

Bird & Bird

Sally is a partner in the Life Sciences and Intellectual Property Group a Bird & Bird LLP, based in London. She qualified at Herbert Smith and spent a few years in the corporate department there. Before her return to private practice in 2001, she had spent 11 years working in-house in senior roles in the Life Sciences industry, including several years as Legal Director of the Novartis Group in the UK. She now specialises in transactional IP work and life sciences regulatory work. She is the editor of the Kluwer Law publication, the EU Guide to Pharmaceutical Regulatory Law and is a regular speaker internationally on all types of IP and regulatory issues. She leads the Bird & Bird initiative in relation to Brexit matters.

Recent matters include:

Advising a multinational pharmaceutical company in relation to the acquisition of sub licences to product portfolios worth $275milllion, and then converting the sub licence portfolio into a head licence.
Working with a major research based hospital in relation to its R&D strategy and agreements for IP exploitation.
Acting for listed advanced chemicals company in relation to its licensing programme and its establishing a supply and manufacturing site on a former chemical manufacturing site.
Advising US medical device companies in relation to challenges to their applications for CE marks for all classes of medical device.
Advising a US biotech on all aspects of its launch into Europe, including clinical trial, agency and distribution agreements, as well as significant licences with pharmaceutical companies.

Contributed to

1

Unlicensed medicinal products and off-label use of medicinal products

Practice Notes

This Practice Note explores unlicensed medicinal products and the various ways that such products may be made available to patients in the EU and UK, including through the UK’s Specials regime. The note goes on to consider the use of licensed medicinal products outside the terms of their authorisation (known as off-label use). Finally, this Practice Note considers liability issues concerning the unlicensed use of medicines.

Life Sciences